Evidence map›Paper›PMID 41939895›Full record

ArticleFrontiers in immunology2026

Prognostic factors in Sézary syndrome - a retrospective propensity score-matched study on 1277 patients.

Nadia Ninosu, Max Kappenstein, Niklas Gebauer, Dagmar von Bubnoff, Nikolas von Bubnoff, Jan P Nicolay

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nadia Ninosu *Department of Dermatology, Allergology and Venerology, University Medical Center Mannheim/Ruprecht Karls University of Heidelberg, Mannheim, Germany.
Max Kappenstein *Department of Nuclear Medicine, University Hospital Frankfurt am Main, Frankfurt am Main, Germany.
Niklas GebauerDepartment of Hematology and Oncology, University Hospital of Schleswig-Holstein, Lübeck, Germany.
Dagmar von BubnoffDepartment of Dermatology, Allergology and Venerology, University Hospital Schleswig-Holstein, Lübeck, Germany.
Nikolas von Bubnoff *Department of Hematology and Oncology, University Hospital of Schleswig-Holstein, Lübeck, Germany.
Jan P Nicolay *Department of Dermatology, Allergology and Venerology, University Medical Center Mannheim/Ruprecht Karls University of Heidelberg, Mannheim, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Sézary syndrome (SS) is a rare neoplasm associated with poor prognosis. Due to the rarity of the disease, large-scale investigations are scarce, while identifying prognostic factors is essential for improving treatment outcomes. The primary objective was to investigate prognostic factors in a large population of SS patients on survival and infections. The secondary objective was to validate a previously suggested prognostic index model. Methods: We conducted a propensity score-matched retrospective cohort study using real-world data from 1277 patients in the TriNetX database. Risk factors examined included age, elevated lactate dehydrogenase (LDH), anemia, elevated white blood cell count (WBC), sex, and race. Examined outcomes were: 5-year survival, Systemic Inflammatory Response Syndrome (SIRS), sepsis and pneumonia. The prognostic index model was simplified into factors assessable through TriNetX. Results: Age > 60 years, elevated LDH, anemia and elevated WBC were risk factors for 5-year overall survival. Elevated LDH, anemia, elevated WBC and African American/black race were significantly associated with sepsis. Anemia and elevated WBC were also linked to higher risk of pneumonia. Additionally, we devised and validated a simplified prognostic index model (sPIM) accounting for patient focus on SS (stage IV) patients. Conclusion: In the largest group of SS patients assessed for risk stratification to-date, we confirm age and elevated LDH as risk factors in SS and their applicability in the prognostic index model. This study introduces anemia as a novel risk factor and demonstrates the prognostic value of leukocytosis in SS. While race requires further investigation, sex appears to have no significant impact on survival.

Indexed as

Sezary SyndromeSkin NeoplasmsAgedAnemiaFemaleHumansMaleMiddle AgedPrognosisPropensity ScoreRetrospective StudiesRisk FactorsanemiaCTCLcutaneous T-cell lymphomaprognostic factorsreal-world datarisk factorsSézary syndromeTriNetX

Identifiers

PMID41939895
PMCPMC13043635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.